MEDIPOST’s CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control
– Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study– Japan…